Search

Your search keyword '"Parreño, Viviana"' showing total 297 results
Start Over Author "Parreño, Viviana"
297 results on '"Parreño, Viviana"'

1. Integrated hepatitis e virus monitoring in central Argentina: a six-year analysis of clinical surveillance and wastewater-based epidemiology

Author

Fantilli, Anabella Clara, Masachessi, Gisela, Cola, Guadalupe Di, Castro, Gonzalo, Sicilia, Paola, Marinzalda, María de los Angeles, Cachi, Ariana Mariela, Moreno, Claudia, Borda, Mariel, Ibarra, Gustavo, Rojas, Ricardo Manuel, Parreño, Viviana Gladys, Barbás, María Gabriela, Nates, Silvia Viviana, Pisano, María Belén, and Ré, Viviana Elizabeth

Published
2024
Full Text
View/download PDF

9. Molecular characterization of multidrug-resistant Escherichia coli of the phylogroups A and C in dairy calves with meningitis and septicemia

Author

Louge Uriarte, Enrique L., González Pasayo, Ramón A., Massó, Mariana, Carrera Paez, Laura, Domínguez Moncla, Manuel, Donis, Nicolás, Malena, Rosana, Méndez, Alejandra, Morrell, Eleonora, Giannitti, Federico, Armendano, Joaquín I., Faverin, Claudia, Centrón, Daniela, Parreño, Viviana, Odeón, Anselmo C., Quiroga, María Paula, and Moreira, Ana Rita

Published
2022
Full Text
View/download PDF

11. IgY Industries and Markets

Author

Vieira-Pires, Ricardo S., Ahn, Hyeong Chul, Bok, Marina, Caulfield, Catherine D., Chacana, Pablo, Elahi, Fazle, Larsson, Anders O., Leiva, Carlos Leónidas, Moran, Leonard M., Morgan, Patricia M., Parreño, Viviana, Vega, Celina G., Wigdorovitz, Andrés, Zhang, Xiao-Ying, editor, Vieira-Pires, Ricardo S., editor, Morgan, Patricia M., editor, and Schade, Rüdiger, editor

Published
2021
Full Text
View/download PDF

15. SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice

Author

Pavan, María Florencia, Bok, Marina, Betanzos San Juan, Rafael, Malito, Juan Pablo, Marcoppido, Gisela Ariana, Franco, Diego Rafael, Militelo, Daniela Ayelen, Schammas, Juan Manuel, Bari, Sara Elizabeth, Stone, William, López, Krisangel, Porier, Danielle LaBrie, Muller, John Anthony, Auguste, Albert Jonathan, Yuan, Lijuan, Wigdorovitz, Andrés, Parreño, Viviana Gladys, Ibañez, Lorena Itat, Pavan, María Florencia, Bok, Marina, Betanzos San Juan, Rafael, Malito, Juan Pablo, Marcoppido, Gisela Ariana, Franco, Diego Rafael, Militelo, Daniela Ayelen, Schammas, Juan Manuel, Bari, Sara Elizabeth, Stone, William, López, Krisangel, Porier, Danielle LaBrie, Muller, John Anthony, Auguste, Albert Jonathan, Yuan, Lijuan, Wigdorovitz, Andrés, Parreño, Viviana Gladys, and Ibañez, Lorena Itat

Abstract

Since the beginning of the COVID-19 pandemic, there has been a significant need to develop antivirals and vaccines to combat the disease. In this work, we developed llama-derived nanobodies (Nbs) directed against the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Most of the Nbs with neutralizing properties were directed to RBD and were able to block S-2P/ACE2 interaction. Three neutralizing Nbs recognized the N-terminal domain (NTD) of the S-2P protein. Intranasal administration of Nbs induced protection ranging from 40% to 80% after challenge with the WA1/2020 strain in k18-hACE2 transgenic mice. Interestingly, protection was associated with a significant reduction in virus replication in nasal turbinates and a reduction in virus load in the brain. Employing pseudovirus neutralization assays, we identified Nbs with neutralizing capacity against the Alpha, Beta, Delta, and Omicron variants, including a Nb capable of neutralizing all variants tested. Furthermore, cocktails of different Nbs performed better than individual Nbs at neutralizing two Omicron variants (B.1.529 and BA.2). Altogether, the data suggest the potential of SARS-CoV-2 specific Nbs for intranasal treatment of COVID-19 encephalitis.

Published
2024

16. Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus

Author

Dalvie, Neil C., Brady, Joseph R., Crowell, Laura E., Tracey, Mary Kate, Biedermann, Andrew M., Kaur, Kawaljit, Hickey, John M., Kristensen, II, D. Lee, Bonnyman, Alexandra D., Rodriguez-Aponte, Sergio A., Whittaker, Charles A., Bok, Marina, Vega, Celina, Mukhopadhyay, Tarit K., Joshi, Sangeeta B., Volkin, David B., Parreño, Viviana, Love, Kerry R., and Love, J. Christopher

Published
2021
Full Text
View/download PDF

19. SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice

Author

Pavan, María Florencia, primary, Bok, Marina, additional, Betanzos San Juan, Rafael, additional, Malito, Juan Pablo, additional, Marcoppido, Gisela Ariana, additional, Franco, Diego Rafael, additional, Militelo, Daniela Ayelen, additional, Schammas, Juan Manuel, additional, Bari, Sara Elizabeth, additional, Stone, William, additional, López, Krisangel, additional, Porier, Danielle LaBrie, additional, Muller, John Anthony, additional, Auguste, Albert Jonathan, additional, Yuan, Lijuan, additional, Wigdorovitz, Andrés, additional, Parreño, Viviana Gladys, additional, and Ibañez, Lorena Itat, additional

Published
2024
Full Text
View/download PDF

23. Molecular Epidemiology of Rotavirus A in Calves: Evolutionary Analysis of a Bovine G8P[11] Strain and Spatio-Temporal Dynamics of G6 Lineages in the Americas

Author

Louge Uriarte, Enrique L., primary, Badaracco, Alejandra, additional, Spetter, Maximiliano J., additional, Miño, Samuel, additional, Armendano, Joaquín I., additional, Zeller, Mark, additional, Heylen, Elisabeth, additional, Späth, Ernesto, additional, Leunda, María Rosa, additional, Moreira, Ana Rita, additional, Matthijnssens, Jelle, additional, Parreño, Viviana, additional, and Odeón, Anselmo C., additional

Published
2023
Full Text
View/download PDF

24. Human Rotavirus Replicates in Salivary Glands and Primes Immune Responses in Facial and Intestinal Lymphoid Tissues of Gnotobiotic Pigs

Author

Nyblade, Charlotte, primary, Zhou, Peng, additional, Frazier, Maggie, additional, Frazier, Annie, additional, Hensley, Casey, additional, Fantasia-Davis, Ariana, additional, Shahrudin, Shabihah, additional, Hoffer, Miranda, additional, Agbemabiese, Chantal Ama, additional, LaRue, Lauren, additional, Barro, Mario, additional, Patton, John T., additional, Parreño, Viviana, additional, and Yuan, Lijuan, additional

Published
2023
Full Text
View/download PDF

28. A Multispecies Competitive Nanobody-Based Elisa for the Detection of Antibodies Against Hepatitis E Virus

Author

Arce, Lorena Paola, primary, Pavan, María Florencia, additional, Bok, Marina, additional, Gutierrez, Silvina Elena, additional, Santos, Agostina Tammone, additional, Condorí, Walter Ezequiel, additional, Uhart, Marcela María, additional, Estein, Silvia Marcela, additional, Parreño, Viviana, additional, Vizoso-Pinto, María Guadalupe, additional, and Ibañez, Lorena Itatí, additional

Published
2023
Full Text
View/download PDF

29. Combined Live Oral Priming and Intramuscular Boosting Regimen with Rotarix® and a Nanoparticle-Based Trivalent Rotavirus Vaccine Evaluated in Gnotobiotic Pig Models of G4P[6] and G1P[8] Human Rotavirus Infection

Author

Hensley, Casey, primary, Nyblade, Charlotte, additional, Zhou, Peng, additional, Parreño, Viviana, additional, Ramesh, Ashwin, additional, Frazier, Annie, additional, Frazier, Maggie, additional, Garrison, Sarah, additional, Fantasia-Davis, Ariana, additional, Cai, Ruiqing, additional, Huang, Peng-Wei, additional, Xia, Ming, additional, Tan, Ming, additional, and Yuan, Lijuan, additional

Published
2023
Full Text
View/download PDF

31. Combined Live Oral Priming and Intramuscular Boosting Regimen with Rotarix® and a Nanoparticle-Based Trivalent Rotavirus Vaccine Evaluated in Gnotobiotic Pig Models of G4P[6] and G1P[8] Human Rotavirus Infection

Author

Hensley, Casey, Nyblade, Charlotte, Zhou, Peng, Parreño, Viviana, Ramesh, Ashwin, Frazier, Annie, Frazier, Maggie, Garrison, Sarah, Fantasia-Davis, Ariana, Cai, Ruiqing, Huang, Peng-Wei, Xia, Ming, Tan, Ming, Yuan, Lijuan, Hensley, Casey, Nyblade, Charlotte, Zhou, Peng, Parreño, Viviana, Ramesh, Ashwin, Frazier, Annie, Frazier, Maggie, Garrison, Sarah, Fantasia-Davis, Ariana, Cai, Ruiqing, Huang, Peng-Wei, Xia, Ming, Tan, Ming, and Yuan, Lijuan

Abstract

Human rotavirus (HRV) is the causative agent of severe dehydrating diarrhea in children under the age of five, resulting in up to 215,000 deaths each year. These deaths almost exclusively occur in low- and middle-income countries where vaccine efficacy is the lowest due to chronic malnutrition, gut dysbiosis, and concurrent enteric viral infection. Parenteral vaccines for HRV are particularly attractive as they avoid many of the concerns associated with currently used live oral vaccines. In this study, a two-dose intramuscular (IM) regimen of the trivalent, nanoparticle-based, nonreplicating HRV vaccine (trivalent S60-VP8*), utilizing the shell (S) domain of the capsid of norovirus as an HRV VP8* antigen display platform, was evaluated for immunogenicity and protective efficacy against P[6] and P[8] HRV using gnotobiotic pig models. A prime–boost strategy using one dose of the oral Rotarix® vaccine, followed by one dose of the IM trivalent nanoparticle vaccine was also evaluated. Both regimens were highly immunogenic in inducing serum virus neutralizing, IgG, and IgA antibodies. The two vaccine regimens failed to confer significant protection against diarrhea; however, the prime–boost regimen significantly shortened the duration of virus shedding in pigs challenged orally with the virulent Wa (G1P[8]) HRV and significantly shortened the mean duration of virus shedding, mean peak titer, and area under the curve of virus shedding after challenge with Arg (G4P[6]) HRV. Prime–boost-vaccinated pigs challenged with P[8] HRV had significantly higher P[8]-specific IgG antibody-secreting cells (ASCs) in the spleen post-challenge. Prime–boost-vaccinated pigs challenged with P[6] HRV had significantly higher numbers of P[6]- and P[8]-specific IgG ASCs in the ileum, as well as significantly higher numbers of P[8]-specific IgA ASCs in the spleen post-challenge. These results suggest the promise of and warrant further investigatio

Published
2023

32. Human Rotavirus Replicates in Salivary Glands and Primes Immune Responses in Facial and Intestinal Lymphoid Tissues of Gnotobiotic Pigs

Author

Nyblade, Charlotte, Zhou, Peng, Frazier, Maggie, Frazier, Annie, Hensley, Casey, Fantasia-Davis, Ariana, Shahrudin, Shabihah, Hoffer, Miranda, Agbemabiese, Chantal Ama, LaRue, Lauren, Barro, Mario, Patton, John T., Parreño, Viviana, Yuan, Lijuan, Nyblade, Charlotte, Zhou, Peng, Frazier, Maggie, Frazier, Annie, Hensley, Casey, Fantasia-Davis, Ariana, Shahrudin, Shabihah, Hoffer, Miranda, Agbemabiese, Chantal Ama, LaRue, Lauren, Barro, Mario, Patton, John T., Parreño, Viviana, and Yuan, Lijuan

Abstract

Human rotavirus (HRV) is a leading cause of viral gastroenteritis in children across the globe. The virus has long been established as a pathogen of the gastrointestinal tract, targeting small intestine epithelial cells and leading to diarrhea, nausea, and vomiting. Recently, this classical infection pathway was challenged by the findings that murine strains of rotavirus can infect the salivary glands of pups and dams and transmit via saliva from pups to dams during suckling. Here, we aimed to determine if HRV was also capable of infecting salivary glands and spreading in saliva using a gnotobiotic (Gn) pig model of HRV infection and disease. Gn pigs were orally inoculated with various strains of HRV, and virus shedding was monitored for several days post-inoculation. HRV was shed nasally and in feces in all inoculated pigs. Infectious HRV was detected in the saliva of four piglets. Structural and non-structural HRV proteins, as well as the HRV genome, were detected in the intestinal and facial tissues of inoculated pigs. The pigs developed high IgM antibody responses in serum and small intestinal contents at 10 days post-inoculation. Additionally, inoculated pigs had HRV-specific IgM antibody-secreting cells present in the ileum, tonsils, and facial lymphoid tissues. Taken together, these findings indicate that HRV can replicate in salivary tissues and prime immune responses in both intestinal and facial lymphoid tissues of Gn pigs.

Published
2023

35. Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants

Author

Pavan, María Florencia, Bok, Marina, Juan, Rafael Betanzos San, Malito, Juan Pablo, Marcoppido, Gisela Ariana, Franco, Diego Rafael, Militello, Daniela Ayelen, Schammas, Juan Manuel, Bari, Sara, Stone, William B., López, Krisangel, Porier, Danielle L., Muller, John, Auguste, Albert J., Yuan, Lijuan, Wigdorovitz, Andrés, Parreño, Viviana, and Ibañez, Lorena Itatí

Subjects
Article
Abstract

In this work, we developed llama-derived nanobodies (Nbs) directed to the receptor binding domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Nanobodies were selected after the biopanning of two VHH-libraries, one of which was generated after the immunization of a llama ( lama glama ) with the bovine coronavirus (BCoV) Mebus, and another with the full-length pre-fused locked S protein (S-2P) and the RBD from the SARS-CoV-2 Wuhan strain (WT). Most of the neutralizing Nbs selected with either RBD or S-2P from SARS-CoV-2 were directed to RBD and were able to block S- 2P/ACE2 interaction. Three Nbs recognized the N-terminal domain (NTD) of the S-2P protein as measured by competition with biliverdin, while some non-neutralizing Nbs recognize epitopes in the S2 domain. One Nb from the BCoV immune library was directed to RBD but was non-neutralizing. Intranasal administration of Nbs induced protection ranging from 40% to 80% against COVID-19 death in k18-hACE2 mice challenged with the WT strain. Interestingly, protection was not only associated with a significant reduction of virus replication in nasal turbinates and lungs, but also with a reduction of virus load in the brain. Employing pseudovirus neutralization assays, we were able to identify Nbs with neutralizing capacity against the Alpha, Beta, Delta and Omicron variants. Furthermore, cocktails of different Nbs performed better than individual Nbs to neutralize two Omicron variants (B.1.529 and BA.2). Altogether, the data suggest these Nbs can potentially be used as a cocktail for intranasal treatment to prevent or treat COVID-19 encephalitis, or modified for prophylactic administration to fight this disease.

Published
2023

38. Quadruplex Real-Time TaqMan ® RT-qPCR Assay for Differentiation of Equine Group A and B Rotaviruses and Identification of Group A G3 and G14 Genotypes.

Author

Carossino, Mariano, Balasuriya, Udeni B. R., Thieulent, Côme J., Barrandeguy, Maria E., Vissani, Maria Aldana, and Parreño, Viviana

Subjects
ROTAVIRUSES, EMERGING infectious diseases, GENOTYPES, VACCINE development, MOLECULAR epidemiology, FOALS
Abstract

Equine rotavirus A (ERVA) is the leading cause of diarrhea in foals, with G3P[12] and G14P[12] genotypes being the most prevalent. Recently, equine G3-like RVA was recognized as an emerging infection in children, and a group B equine rotavirus (ERVB) was identified as an emergent cause of foal diarrhea in the US. Thus, there is a need to adapt molecular diagnostic tools for improved detection and surveillance to identify emerging strains, understand their molecular epidemiology, and inform future vaccine development. We developed a quadruplex TaqMan® RT-qPCR assay for differentiation of ERVA and ERVB and simultaneous G-typing of ERVA strains, evaluated its analytical and clinical performance, and compared it to (1) a previously established ERVA triplex RT-qPCR assay and (2) standard RT-PCR assay and Sanger sequencing of PCR products. This quadruplex RT-qPCR assay demonstrated high sensitivity (>90%)/specificity (100%) for every target and high overall agreement (>96%). Comparison between the triplex and quadruplex assays revealed only a slightly higher sensitivity for the ERVA NSP3 target using the triplex format (p-value 0.008) while no significant differences were detected for other targets. This quadruplex RT-qPCR assay will significantly enhance rapid surveillance of both ERVA and ERVB circulating and emerging strains with potential for interspecies transmission. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Anticuerpos de yema de huevo frente a la diarrea neonatal del ternero.

Author

Parreño, Viviana

Subjects
ESCHERICHIA coli, ROTAVIRUS diseases, CALVES, MATERNALLY acquired immunity, ANIMAL health, DIARRHEA, COVID-19, IMMUNITY, EGG yolk, ROTAVIRUSES, CORONAVIRUSES
Abstract

Copyright of Albéitar is the property of Grupo Asis Biomedia, S.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024

42. Combined Live Oral Priming and Intramuscular Boosting Regimen with Rotarix ® and a Nanoparticle-Based Trivalent Rotavirus Vaccine Evaluated in Gnotobiotic Pig Models of G4P[6] and G1P[8] Human Rotavirus Infection.

Author

Hensley, Casey, Nyblade, Charlotte, Zhou, Peng, Parreño, Viviana, Ramesh, Ashwin, Frazier, Annie, Frazier, Maggie, Garrison, Sarah, Fantasia-Davis, Ariana, Cai, Ruiqing, Huang, Peng-Wei, Xia, Ming, Tan, Ming, and Yuan, Lijuan

Subjects
ROTAVIRUS diseases, COMBINED vaccines, ROTAVIRUS vaccines, ORAL vaccines, DRYING agents
Abstract

Human rotavirus (HRV) is the causative agent of severe dehydrating diarrhea in children under the age of five, resulting in up to 215,000 deaths each year. These deaths almost exclusively occur in low- and middle-income countries where vaccine efficacy is the lowest due to chronic malnutrition, gut dysbiosis, and concurrent enteric viral infection. Parenteral vaccines for HRV are particularly attractive as they avoid many of the concerns associated with currently used live oral vaccines. In this study, a two-dose intramuscular (IM) regimen of the trivalent, nanoparticle-based, nonreplicating HRV vaccine (trivalent S60-VP8*), utilizing the shell (S) domain of the capsid of norovirus as an HRV VP8* antigen display platform, was evaluated for immunogenicity and protective efficacy against P[6] and P[8] HRV using gnotobiotic pig models. A prime–boost strategy using one dose of the oral Rotarix® vaccine, followed by one dose of the IM trivalent nanoparticle vaccine was also evaluated. Both regimens were highly immunogenic in inducing serum virus neutralizing, IgG, and IgA antibodies. The two vaccine regimens failed to confer significant protection against diarrhea; however, the prime–boost regimen significantly shortened the duration of virus shedding in pigs challenged orally with the virulent Wa (G1P[8]) HRV and significantly shortened the mean duration of virus shedding, mean peak titer, and area under the curve of virus shedding after challenge with Arg (G4P[6]) HRV. Prime–boost-vaccinated pigs challenged with P[8] HRV had significantly higher P[8]-specific IgG antibody-secreting cells (ASCs) in the spleen post-challenge. Prime–boost-vaccinated pigs challenged with P[6] HRV had significantly higher numbers of P[6]- and P[8]-specific IgG ASCs in the ileum, as well as significantly higher numbers of P[8]-specific IgA ASCs in the spleen post-challenge. These results suggest the promise of and warrant further investigation into the oral priming and parenteral boosting strategy for future HRV vaccines. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection

Author

Artman, Chad, Idegwu, Nnebuefe, Brumfield, Kyle D., Lai, Ken, Hauta, Shirley, Falzarano, Darryl, Parreño, Viviana, Yuan, Lijuan, Geyer, James D., Goepp, Julius G., Artman, Chad, Idegwu, Nnebuefe, Brumfield, Kyle D., Lai, Ken, Hauta, Shirley, Falzarano, Darryl, Parreño, Viviana, Yuan, Lijuan, Geyer, James D., and Goepp, Julius G.

Abstract

Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.

Published
2022

45. A New Gnotobiotic Pig Model of P[6] Human Rotavirus Infection and Disease for Preclinical Evaluation of Rotavirus Vaccines

Author

Nyblade, Charlotte, Hensley, Casey, Parreño, Viviana, Zhou, Peng, Frazier, Maggie, Frazier, Annie, Ramesh, Ashwin, Lei, Shaohua, Degiuseppe, Juan Ignacio, Tan, Ming, Yuan, Lijuan, Nyblade, Charlotte, Hensley, Casey, Parreño, Viviana, Zhou, Peng, Frazier, Maggie, Frazier, Annie, Ramesh, Ashwin, Lei, Shaohua, Degiuseppe, Juan Ignacio, Tan, Ming, and Yuan, Lijuan

Abstract

Human rotavirus (HRV) is a leading cause of gastroenteritis in children under 5 years of age. Licensed vaccines containing G1P[8] and G1-4P[8] strains are less efficacious against newly emerging P[6] strains, indicating an urgent need for better cross protective vaccines. Here, we report our development of a new gnotobiotic (Gn) pig model of P[6] HRV infection and disease as a tool for evaluating potential vaccine candidates. The Arg HRV (G4P[6]) strain was derived from a diarrheic human infant stool sample and determined to be free of other viruses by metagenomic sequencing. Neonatal Gn pigs were orally inoculated with the stool suspension containing 5.6 × 105 fluorescent focus units (FFU) of the virus. Small and large intestinal contents were collected at post inoculation day 2 or 3. The virus was passaged 6 times in neonatal Gn pigs to generate a large inoculum pool. Next, 33–34 day old Gn pigs were orally inoculated with 10−2, 103, 104, and 105 FFU of Arg HRV to determine the optimal challenge dose. All pigs developed clinical signs of infection, regardless of the inoculum dose. The optimal challenge dose was determined to be 105 FFU. This new Gn pig model is ready to be used to assess the protective efficacy of candidate monovalent and multivalent vaccines against P[6] HRV.

Published
2022

47. Human norovirus animal model essential for vaccine development

Author

Yuan, Lijuan, Parreño, Viviana, and Ramesh, Ashwin

Subjects
viruses, virus diseases
Abstract

Human noroviruses are the most common cause of acute gastroenteritis and represent an incredibly high burden on the healthcare sector. Currently no vaccines or drugs exist to prevent or treat the disease. This is in part due to a lack of animal models. Here, Dr Lijuan Yuan and the team at Virginia Polytechnic Institute and State University developed and validated gnotobiotic pigs as an animal model for the human norovirus GII.4/2003 Cin-2. Determining dose-response relationships as well as the median infectious dose, by using different statistical approaches for this virus, means we are one step closer on the path to vaccine development. Published version

Published
2021

50. Contributors

Author

Abadie, Valérie, primary, Abraham, Clara, additional, Adams, David H., additional, Agace, William W., additional, Alexander-Brett, Jennifer, additional, Alkhairy, Omar, additional, Ambite, Ines, additional, Anderson, Deborah J., additional, Artis, David, additional, Atmar, Robert L., additional, Aymeric, Laetitia, additional, Bachert, Claus, additional, Bakema, Jantine E., additional, Baker, Kristi, additional, Beagley, Kenneth W., additional, Befus, A.D., additional, Bemark, Mats, additional, Berin, M. Cecilia, additional, Berings, Margot, additional, Berzofsky, Jay A., additional, Bilej, Martin, additional, Biswas, Nabanita, additional, Blumberg, Richard S., additional, Bienenstock, John, additional, Bogdanos, Dimitrios, additional, Boirivant, Monica, additional, Boonnak, Kobporn, additional, Bracke, Ken R., additional, Brandtzaeg, Per, additional, Braun, Jonathan, additional, Bringer, Marie-Agnès, additional, Broadbent, Andrew J., additional, Bronson, Richard, additional, Brusselle, Guy G., additional, Bulmer, Judith N., additional, Butler, J.E., additional, Cardenas, Paul A., additional, Cebra, John J., additional, Cella, Marina, additional, Cerutti, Andrea, additional, Challacombe, Stephen J., additional, Chattha, Kuldeep, additional, Cheroutre, Hilde, additional, Chiba, Tsutomu, additional, Chorny, Alejo, additional, Clements, John D., additional, Colonna, Marco, additional, Cookson, William O.C., additional, Corbeil, Lynette B., additional, Corthésy, Blaise, additional, Cripps, Allan W., additional, van Crombruggen, Koen, additional, Pires da Cunha, Andre, additional, Cunningham-Rundles, Susanna, additional, Curtiss, Roy, additional, Darfeuille-Michaud, Arlette, additional, de Jonge, Wouter J., additional, Deban, Livija, additional, Denning, Timothy L., additional, Di Santo, James P., additional, Diefenbach, Andreas, additional, DiRita, Victor J., additional, Downey, Jordan, additional, Du, Ming-Qing, additional, Edelblum, Karen L., additional, van Egmond, Marjolein, additional, Epple, H.-J., additional, Fagarasan, Sidonia, additional, Fahey, John V., additional, Ferris, Michael J., additional, Fichtner-Feigl, Stefan, additional, Fidel, Paul L., additional, Flach, Melanie, additional, Flavell, Richard, additional, Fleit, Howard B., additional, Franchini, Genoveffa, additional, Freytag, Lucy C., additional, Fuchs, Anja, additional, Fujihashi, kohtaro, additional, Fuss, Ivan J., additional, Gagliani, Nicola, additional, Garcia, Marta Rodriguez, additional, Garrett, Wendy S., additional, Gershwin, M. Eric, additional, Gevaert, Philippe, additional, Gleeson, Maree, additional, Godaly, Gabriela, additional, Goldblum, Randall M., additional, Gour, Naina, additional, Gursel, Mayda, additional, Hajishengallis, George, additional, Hammad, Hamida, additional, Hammarström, Lennart, additional, Hänninen, Arno, additional, Hanson, Lars Å., additional, Hayday, Adrian, additional, Herzog, Ronit, additional, Hodgins, Douglas C., additional, Holgate, Stephen T., additional, Holmgren, Jan, additional, Holtzman, Michael J., additional, Hook, Edward W., additional, Huber, Samuel, additional, Hurwitz, Julia L., additional, Ivanyi, Juraj, additional, Iwasaki, Akiko, additional, Jabri, Bana, additional, Jackson, Susan, additional, Jacobs, Jonathan, additional, Jalkanen, Sirpa, additional, Janoff, Edward N., additional, Jerse, Ann E., additional, Jeyanathan, Mangalakumari, additional, Julian, Bruce A., additional, Kacskovics, Imre, additional, Kaetzel, Charlotte S., additional, Kaushic, Charu, additional, Kelsall, Brian L., additional, Kessans, Sarah, additional, Kesselring, Rebecca, additional, Kilian, Mogens, additional, Kiyono, Hiroshi, additional, Klinman, Dennis M., additional, Korotkova, Marina, additional, Kronenberg, Mitchell, additional, Krysko, Olga, additional, Kurono, Yuichi, additional, Kverka, Miloslav, additional, Lambrecht, Bart N., additional, Lamm, Michael E., additional, Lantz, Olivier, additional, Lash, Gendie E., additional, Lavelle, E.C., additional, Lefrancois, Leo, additional, Leung, Patrick S.C., additional, Levine, Myron M., additional, Lim, David J., additional, Lippolis, John, additional, Louis, Nancy A., additional, Luster, Andrew D., additional, Lutay, Nataliya, additional, Lycke, Nils, additional, Macpherson, Andrew J., additional, Mantis, Nicholas J., additional, Marcotte, Harold, additional, Martin, David H., additional, Mason, Hugh S., additional, Massa, Helen M., additional, Matoba, Nobuyuki, additional, Mayer, Lloyd, additional, Maynard, Craig L., additional, McElrath, M. Juliana, additional, McEntee, C., additional, McGhee, Jerry R., additional, McGuckin, Michael A., additional, Mestecky, Jiri, additional, Mikhak, Zamaneh, additional, Miller, Robert D., additional, Moldoveanu, Zina, additional, Montgomery, Paul C., additional, Mor, Tsafrir, additional, Neurath, Markus F., additional, Neyt, Katrijn, additional, Nicholson, Lindsay K., additional, Novak, Jan, additional, Nowicki, Stella, additional, O’Hagan, D.T., additional, O’Sullivan, Nancy L., additional, Ogra, Pearay, additional, Orihuela, Carlos, additional, Ouellette, André J., additional, Owen, Robert L., additional, Pabst, Oliver, additional, Parkos, Charles A., additional, Parreño, Viviana, additional, Patel, Mickey V., additional, Perez-Novo, Claudina, additional, Perkins, Darren J., additional, Prussin, Calman, additional, Pudney, Jeffrey, additional, Raghavan, Sukanya, additional, Rainard, Pascal, additional, Ramani, Sasirekha, additional, Randall, Troy D., additional, Raska, Milan, additional, Renukaradhya, Gourapura J., additional, Rescigno, Maria, additional, Rosenthal, Kenneth L., additional, Rothenberg, Marc E., additional, Ruemmele, Frank M., additional, Russell, Michael W., additional, Saif, Linda J., additional, Salinas, Irene, additional, Salmi, Marko, additional, Salmon, Henri, additional, Sampson, Hugh A., additional, Sansonetti, Philippe, additional, Schneider, T., additional, Serafini, Nicolas, additional, Sharma, Dolly, additional, Shen, Zheng, additional, Shi, Hai Ning, additional, Shirlaw, Penelope J., additional, Shivhare, Sourima B., additional, Smith, Phillip D., additional, Smith, Patrick M., additional, Smith, Daniel J., additional, Smythies, Lesley E., additional, Spencer, Jo, additional, Strober, Warren, additional, Subbarao, Kanta, additional, Svanborg, Catharina, additional, Svennerholm, Ann-Mari, additional, Taubman, Martin A., additional, Telemo, Esbjörn, additional, Thornhill, Martin H., additional, Thornton, David J., additional, Thuenemann, Eva, additional, Tlaskalova-Hogenova, Helena, additional, Tristram, Debra, additional, Trivedi, Palak, additional, Tuomanen, Elaine, additional, Turanek, Jaroslav, additional, Turner, Jerrold R., additional, Underdown, Brian J., additional, van Helden, Mary J., additional, Veazey, Ronald S., additional, Verdu, Elena F., additional, Vlasova, Anastasia, additional, Vliagoftis, Harissios, additional, Vogel, Stefanie N., additional, Walker, W. Allan, additional, Wang, Xiaolei, additional, Watanabe, Tomohiro, additional, Weaver, Casey T., additional, Weiner, Howard L., additional, Wells, Jerry M., additional, Wen, Ting, additional, Whittum-Hudson, Judith, additional, Whitsett, Jeffrey A., additional, Williams, Ifor R., additional, Wills-Karp, Marsha, additional, Wira, Charles R., additional, Woof, Jenny M., additional, Wotherspoon, Andrew C., additional, Xing, Zhou, additional, Xu, Huanbin, additional, Zaph, Colby, additional, Zeissig, Sebastian, additional, and Zeitz, M., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results